© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
February 26, 2021
The European Commission is reviewing data from the pivotal phase 3 CheckMate-9ER trial.
February 22, 2021
Adding the off-the-shelf, cell-based immunotherapy ilixadencel to frontline sunitinib was associated with an overall survival benefit in patients with metastatic renal cell carcinoma.
February 19, 2021
Motzer highlights the overall survival benefit achieved with the combination of the PD-1 inhibitor and the multikinase inhibitor versus standard sunitinib in the phase 3 CLEAR trial.
February 11, 2021
The study assessed factors associated with survival outcomes in patients with metastatic clear cell renal cell carcinoma receiving immune checkpoint inhibitors.
February 04, 2021
Published data show the PD-1 inhibitor induced strong antitumor activity in patients with both advanced clear cell renal cell carcinoma (ccRCC) and advanced non-ccRCC.
January 25, 2021
The phase 3 ZIRCON trial is assessing TLX250-CDx as a noninvasive tool to identify clear cell renal cell carcinoma in patients with indeterminate renal masses.
January 22, 2021
The approval is based on data from the phase 3 CheckMate-9ER trial.
January 20, 2021
Hear from key opinion leaders in the urology space as they discuss 2 complex cases across the multidisciplinary approach in upper tract urothelial carcinoma and an incidentally discovered renal mass.
January 13, 2021
Ramaprasad Srinivasan, MD, PhD, provides background on the prognosis and treatment of patients with Von Hippel-Lindau–associated renal cell carcinoma and highlights the novel agent MK-6482.
January 12, 2021
Register for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma.
January 11, 2021
A large review showed that cancer specific survival was improved in overweight and obese patients with renal cell carcinoma compared with patients with normal BMI.
January 04, 2021
Combining telaglenastat with cabozantinib did not improve outcomes versus cabozantinib alone in a phase 2 trial.
December 22, 2020
Improvements in technology have renewed interest in the technique.
December 18, 2020
Over 90% of patients in a phase 2 trial had at least some decrease in the size of target lesions.
December 17, 2020
The comprehensive review includes key developments in both clear cell and non-clear cell histology.
December 02, 2020
Recent research has revived the controversy regarding the role
of cytoreductive nephrectomy in this setting.
November 17, 2020
Rana R. McKay, MD, highlights developments with immunotherapy and targeted agents in the treatment paradigm for non-clear cell renal cell carcinoma.
November 10, 2020
Findings from the phase 3 KEYNOTE-581/CLEAR trial (Study 307) showed that the combination improved overall survival, progression-free survival, and response versus sunitinib.
November 09, 2020
"There is unmet medical need in trying to determine if there is a differential benefit to using one therapy over another in the non-clear cell setting," Thomas E. Hutson, DO, PharmD.
November 06, 2020
Among a small group of patients with metastatic renal cell carcinoma who developed acute interstitial nephritis while on immune checkpoint therapy, 100% had a durable response to treatment.